Drugs /

vincristine liposomal

Back to Drugs List

Overview

Generic Name(s):
lipid-encapsulated vincristine, liposomal vincristine, vincristine, liposomal, and vincristine liposome
NCI Definition [1]:
A liposomal formulation of Vincristine designed to reduce toxicity and improve efficacy. Vincristine binds irreversibly to microtubules and spindle proteins in S phase of the cell cycle and interferes with the formation of the mitotic spindle, thereby arresting tumor cells in metaphase. This agent also depolymerizes microtubules and may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI)

Clinical Trials

View Clinical Trials for vincristine liposomal

Vincristine liposomal has been investigated in 10 clinical trials, of which 9 are open and 1 is closed. Of the trials investigating vincristine liposomal, 3 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), 2 are phase 2 (2 open), 2 are phase 3 (2 open), and 1 is no phase specified (1 open).

BCR-ABL1 Fusion, t(9;22)(q34;q11), and BCL2 Fusion are the most frequent biomarker inclusion criteria for vincristine liposomal clinical trials.

Acute lymphoblastic leukemia, anaplastic ependymoma, and B-cell acute lymphoblastic leukemia are the most common diseases being investigated in vincristine liposomal clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Vincristine Liposomal
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Vincristine Liposomal
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating vincristine liposomal and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
vincristine, liposomal, vincristine liposome, vincaxome, vincacine, onco tcs, liposomal vincristine, lipid-encapsulated vincristine
NCIT ID [1]:
C2104
SNOMED ID [1]:
F-63645

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.